CARSGEN-B(02171),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02171 CARSGEN-B

Market Closed 04-17 16:08:09

12.740

+0.400

+3.24%

High13.260	Low12.320	Vol1.52M
Open12.420	D1 Closing12.340	Amplitude7.62%
Mkt Cap7.30B	Tradable Cap7.30B	Total Shares573.00M
T/O19.46M	T/O Rate0.26%	Tradable Shares573.00M
P/B6.50	ROE-55.84%	EPS-1.53
52wk High19.780	52wk Low2.480	P/E-8.30
Dividend0.00	Div.Yield0.00	ROA-23.91%

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"CARSGEN-B","latestPrice":12.74,"timestamp":1744877289030,"preClose":12.34,"halted":0,"volume":1516500,"delay":0,"floatShares":573000000,"shares":573000000,"eps":-1.5348757249373093,"marketStatus":"Market Closed","change":0.4,"latestTime":"04-17 16:08:09","open":12.42,"high":13.26,"low":12.32,"amount":19457730,"amplitude":0.076175,"askPrice":12.74,"askSize":5500,"bidPrice":12.66,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.5348757249373093,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":7,"adr":0,"listingDate":1623945600000,"exchange":"SEHK","adjPreClose":12.34,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"volumeRatio":0.7210784080677147,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171","defaultTab":"news","newsList":[{"id":"2520974402","title":"CARsgen Therapeutics Widens Loss in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2520974402","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520974402?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 17:54","pubTimestamp":1742378094,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics  widened its attributable loss for the year 2024 to 798.1 million yuan from 747.8 million yuan in the year-ago period, a Tuesday filing with the Hong Kong bourse stated.Loss per share was 1.44 yuan, up from 1.34 yuan in the corresponding period of the last fiscal year.Revenue for the year stood at 39.4 million yuan, while the company recorded no revenue in 2023.The biopharmaceutical company attributed the widened loss mainly to an increase in other net losses.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1585","BK1574","LENZ","02171","BK1587","BK4139"],"gpt_icon":0},{"id":"2520968343","title":"CARsgen Announced 2024 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520968343","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520968343?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 08:15","pubTimestamp":1742343303,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA28X0LD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","BK1585","BK1587","02171"],"gpt_icon":0},{"id":"2520968934","title":"Press Release: CARsgen Announced 2024 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520968934","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520968934?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 08:15","pubTimestamp":1742343300,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 18, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on developing innovative CAR T-cell therapies, announced its 2024 Annual Results.-- Zevor-cel was approved by China's National Medical Products. -- As of December 31, 2024, certification and filings for zevor-cel. completed in 23 provinces or cities, covering over 200 healthcare. institutes; CARsgen has received a total of 154 valid orders from its. enrollment has been completed, and the study has met its primary. published in Nature Medicine and at the 2024 ASCO Annual Meeting.-- The results of the IIT of an allogeneic BCMA-targeting CAR-T product. -- Introduced Zhuhai SB Xinchuang to accelerate allogeneic CAR-T development. Zevorcabtagene autoleucel  is an autologous fully human CAR T-cell product against B-cell maturation antigen . On February 23, 2024, zevor-cel was approved by China's NMPA for the treatment of adult patients with relapsed or refractory multiple myeloma  who have prog","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK1161","02171","BK4232","BK4099","BK4195","BK4230","BK4017","CAR","BK4211","CDE","BK4588","BK4585","R","TM","BK1585","03160","BK4555","BK1574","BK4604","BK4022","BK4209","PC","BK1587"],"gpt_icon":1},{"id":"2520017026","title":"BRIEF-CARsgen Therapeutics Says Net Loss Was Around RMB798 Mln For Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2520017026","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520017026?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 23:01","pubTimestamp":1742310104,"startTime":"0","endTime":"0","summary":"BRIEF-CARsgen Therapeutics Says Net Loss Was Around RMB798 Mln For YearMarch 18  - CARsgen Therapeutics Holdings Ltd 2171.HK:NET LOSS WAS AROUND RMB798 MILLION FOR YEARGROUP'S REVENUE WAS AROUND RMB39.4 MILLION FOR YEARFurther company coverage: 2171.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q1054:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1161","BK1585","BK1574","BK1587"],"gpt_icon":0},{"id":"2520296976","title":"Carsgen Therapeutics Posts FY Net Income RMB -798 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2520296976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520296976?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 19:25","pubTimestamp":1742297138,"startTime":"0","endTime":"0","summary":"March 18 (Reuters) - CARsgen Therapeutics Holdings Ltd <2171.HK>::*FY CAPEX RMB 20 MILLION*FY ADJUSTED NET INCOME RMB -789 MILLION*FY NET INCOME RMB -798 MILLION*Further company coverage: 2171.HK* ((R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nRSD1zV2BZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02171","BK1585","BK1587","BK1161","BK1574"],"gpt_icon":0},{"id":"2520623599","title":"CARsgen Therapeutics Holdings Ltd - Net Loss Was Around RMB798 Mln for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2520623599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520623599?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 19:00","pubTimestamp":1742295634,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q1054:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","02171","BK1574","BK1585"],"gpt_icon":0},{"id":"2520762351","title":"CARsgen Therapeutics Holdings FY Capex RMB 20 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520762351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520762351?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 19:00","pubTimestamp":1742295633,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nPLX426F2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1585","02171","BK1587","BK1574","BK1161"],"gpt_icon":0},{"id":"2516930525","title":"CARsgen's Claudin18.2 CAR-T Therapy Satri-Cel Granted Breakthrough Therapy Designation by the Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2516930525","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516930525?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 08:15","pubTimestamp":1740960905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUANP7GF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1161","02171","BK1585","BK1574"],"gpt_icon":0},{"id":"2514987977","title":"CARsgen Therapeutics to Trim Stake in Biotech Arm After Third-Party Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2514987977","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514987977?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 18:13","pubTimestamp":1740651198,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics'  equity interest in subsidiary, UCARsgen Biotech, will decline to 92% from 100% after an investment fund subscribes for its additional registered capital for 80 million yuan, a Wednesday filing with the Hong Kong bourse said.The investment fund is being managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management, according to the biopharmaceutical company.Under the contract, UCARsgen Biotech has secured the exclusive rights for the R&D, manufacture, and commercialization of two allogeneic CAR-T products in mainland China.UCARsgen Biotech is a new drug discovery biotechnology company focused on allogeneic CAR-T cell therapies for the treatment of hematologic malignancies.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK1585","02171","BK4585","BK1574","IE00BMPRXN33.USD","BK4543","BK4588","BK1587","BK4141","BK1161","BK4609","BK4139","LU0348723411.USD","IE00BMPRXQ63.HKD","IE00BMPRXR70.SGD"],"gpt_icon":1},{"id":"2514854243","title":"BRIEF-Carsgen Therapeutics Says Introduction Of Zhuhai Sb Xinchuang In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514854243","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514854243?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 23:41","pubTimestamp":1740584468,"startTime":"0","endTime":"0","summary":"BRIEF-Carsgen Therapeutics Says Introduction Of Zhuhai Sb Xinchuang In ChinaFeb 26 (Reuters) - CARsgen Therapeutics 2171.HK:INTRODUCTION OF ZHUHAI SB XINCHUANG TO ACCELERATE ALLOGENEIC CAR-T CELL PROD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","02171","BK1161","BK1587","BK1574"],"gpt_icon":0},{"id":"2514885860","title":"CARsgen Therapeutics - Introduction of Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514885860","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514885860?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:50","pubTimestamp":1740577818,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1585","BK1161","02171","BK1587"],"gpt_icon":0},{"id":"2514858139","title":"CARsgen Therapeutics -  Investment Fund to Subscribe for Additional Registered Capital of Ucarsgen Biotech for RMB80 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514858139","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514858139?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:50","pubTimestamp":1740577818,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1JN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1585","BK1161","02171","BK1574","BK1587"],"gpt_icon":0},{"id":"2514609671","title":"CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514609671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514609671?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:01","pubTimestamp":1740488473,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0KF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02171","BK1585","BK1587","BK1161","BK1574"],"gpt_icon":0},{"id":"2506682765","title":"CARsgen Therapeutics Holdings Limited's (HKG:2171) stock price dropped 6.5% last week; retail investors would not be happy","url":"https://stock-news.laohu8.com/highlight/detail?id=2506682765","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506682765?lang=en_us&edition=full_marsco","pubTime":"2025-01-28 07:41","pubTimestamp":1738021302,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by retail investors in CARsgen Therapeutics Holdings indicates that they...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/carsgen-therapeutics-holdings-limiteds-hkg2171-stock-price-d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LENZ","BK1587","02171","BK1574","BK1161","BK1585"],"gpt_icon":0},{"id":"2503930292","title":"CARsgen's Allogeneic Cd19/Cd20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503930292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503930292?lang=en_us&edition=full_marsco","pubTime":"2025-01-13 21:50","pubTimestamp":1736776232,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O913Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1585","02171","BK1587","BK1574","BK1161"],"gpt_icon":0},{"id":"2495904426","title":"CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic Cd19/Cd20 CAR-T Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2495904426","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495904426?lang=en_us&edition=full_marsco","pubTime":"2024-12-31 21:50","pubTimestamp":1735653003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241231:nTUA50SJMG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","02171","BK1585","BK1574"],"gpt_icon":0},{"id":"1145734059","title":"Stock Track | CARsgen-B Soars 5.98% on Positive Topline Results from Phase II CAR-T Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1145734059","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145734059?lang=en_us&edition=full_marsco","pubTime":"2024-12-31 09:37","pubTimestamp":1735609022,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings Ltd , a leading biotech company, witnessed a significant surge of 5.98% in its stock price during the intraday trading session on Tuesday.This rally can be attributed to the company's announcement of positive topline results from a pivotal Phase II clinical trial in China for its Claudin18.2 CAR-T cell therapy, SATRI-CEL. The study met its primary endpoint of improved progression-free survival , showcasing the therapy's potential efficacy in treating gastric cancer ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02171"],"gpt_icon":0},{"id":"2495529665","title":"BRIEF-CARsgen Announces Topline Results From China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T","url":"https://stock-news.laohu8.com/highlight/detail?id=2495529665","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495529665?lang=en_us&edition=full_marsco","pubTime":"2024-12-30 23:21","pubTimestamp":1735572084,"startTime":"0","endTime":"0","summary":"Dec 30  - CARsgen Therapeutics Holdings Ltd :   * CARSGEN ANNOUNCES POSITIVE TOPLINE RESULTS FROM CHINA GC/GEJ PIVOTAL PHASE II CLINICAL TRIAL OF CLAUDIN18.2 CAR-T    * CARSGEN THERAPEUTICS HOLDINGS LTD - STUDY MEETS PRIMARY ENDPOINT OF IMPROVED PFS   * CARSGEN THERAPEUTICS HOLDINGS LTD: ANTICIPATE SUBMITTING AN NDA TO NMPA IN FIRST HALF OF 2025Source text:    Further company coverage:    ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-CARsgen Announces Topline Results From China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1585","BK1587","02171","BK1161"],"gpt_icon":0},{"id":"2495688547","title":"CARsgen Therapeutics Holdings Ltd: Anticipate Submitting an Nda to Nmpa in First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2495688547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495688547?lang=en_us&edition=full_marsco","pubTime":"2024-12-30 21:50","pubTimestamp":1735566602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nTUABMZCQY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1585","BK1161","BK1587","02171","BK1574"],"gpt_icon":0},{"id":"2495547560","title":"CARsgen Announces Positive Topline Results From China GC/Gej Pivotal Phase Ii Clinical Trial of Claudin18.2 CAR-T (Satri-Cel)","url":"https://stock-news.laohu8.com/highlight/detail?id=2495547560","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495547560?lang=en_us&edition=full_marsco","pubTime":"2024-12-30 21:50","pubTimestamp":1735566602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nTUABMZCQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1585","02171","BK1161","BK1587","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":0.1603},{"period":"1month","weight":-0.0348},{"period":"3month","weight":0.2417},{"period":"6month","weight":2.1771},{"period":"1year","weight":1.8374},{"period":"ytd","weight":0.3833}],"compareEarnings":[{"period":"1week","weight":0.0345},{"period":"1month","weight":-0.1352},{"period":"3month","weight":0.0925},{"period":"6month","weight":0.0284},{"period":"1year","weight":0.3165},{"period":"ytd","weight":0.0666}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.109168},{"month":2,"riseRate":0.75,"avgChangeRate":0.310052},{"month":3,"riseRate":0,"avgChangeRate":-0.128154},{"month":4,"riseRate":0,"avgChangeRate":-0.13771},{"month":5,"riseRate":0.666667,"avgChangeRate":0.010432},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.000476},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003478},{"month":8,"riseRate":0.5,"avgChangeRate":0.066002},{"month":9,"riseRate":0.5,"avgChangeRate":0.083194},{"month":10,"riseRate":0.75,"avgChangeRate":0.067361},{"month":11,"riseRate":0.5,"avgChangeRate":0.049974},{"month":12,"riseRate":0.5,"avgChangeRate":-0.036587}],"exchange":"SEHK","name":"CARSGEN-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CARSGEN-B(02171),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CARSGEN-B(02171) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CARSGEN-B,02171,CARSGEN-B股票,CARSGEN-B股票老虎,CARSGEN-B股票老虎国际,CARSGEN-B行情,CARSGEN-B股票行情,CARSGEN-B股价,CARSGEN-B股市,CARSGEN-B股票价格,CARSGEN-B股票交易,CARSGEN-B股票购买,CARSGEN-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CARSGEN-B(02171),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CARSGEN-B(02171) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}